Table 2.
The effect of ERT on bilirubin and total antioxidant status in patients with FD.
| ERT+ (n = 31) | ERT− (n = 25) | Controls (n = 185) | p value | |
|---|---|---|---|---|
| Males + females | ||||
| Bilirubin [μmol/L] | 9.7 [8.6–15.5] | 7.2 [5.6–8.7] | 0.004 | |
| TAS | 7.14 ± 1.9 | 6.10 ± 1.2 | 0.036 | |
| 6.10 ± 1.2 | 6.92 ± 2 | 0.059 | ||
| 7.14 ± 1.9 | 6.92 ± 2 | 0.503 | ||
| Males∗ | ||||
| TAS | 7.3 ± 2 (n = 21) | (n = 2) | 7.43 ± 1.9 (n = 108) | 0.794 |
| Females | ||||
| Bilirubin [μmol/L] | 8.9 ± 0.8 (n = 10) | 7.5 ± 1.9 (n = 23) | 0.186 | |
| TAS | 6.5 [5.5–7.6] | 5.8 [5.2–7.4] | 0.201 | |
| 6.5 [5.5–7.6] | 6.0 [4.8–7.2] (n = 77) | 0.235 | ||
Out of the entire group, 55% of patients were treated with ERT (enzyme replacement therapy) (95% men and 30% women). TAS, total antioxidant status, was determined according to [26]. FD: Fabry disease. ∗Only two male FD patients were untreated with ERT, making comparison with the untreated group impossible.